A TREATMENT for men with advanced prostate cancer has been approved for use on the NHS in Scotland.

An expert at the Beatson West of Scotland Cancer Centre, Professor Rob Jones has welcomed the decision to offer suitable men the therapy known as radium-223 dichloride.

Scotland is said to be the first and only country in the UK to grant sustained access to the treatment for a specific set of patients.

Prostate cancer is the most common male cancer in Scotland, with almost 15,000 cases between 2008 and 2012, and the number of cases is projected to increase by 35 per cent within the next 10 years. In some the disease can spread to other parts

of the body, particularly the bones, leading to pain and potential fractures.

Professor Jones, honorary consultant in medical oncology at the Beatson West of Scotland Cancer Centre, said: “Around 900 men a year die from prostate cancer in Scotland. In the majority of these

men, the cancer will have spread to the bones and this can cause a lot of problems such as pain, fracture and paralysis. The availability of radium-223 dichloride is welcome news

for men living with advanced prostate cancer and their families as this is a treatment which specifically targets the bones improving pain control and preventing other complications as well as prolonging survival. I am pleased that Scotland has recognised

the challenges that bone metastases can pose to patients with advanced stages of this cancer."

In trials median survival was extended by more than three months in patients who took the treatment. Some patients suffered side effects.